114 related articles for article (PubMed ID: 8276300)
1. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.
Tropé C; Kaern J; Vergote IB; Kristensen G; Abeler V
Gynecol Oncol; 1993 Nov; 51(2):236-43. PubMed ID: 8276300
[TBL] [Abstract][Full Text] [Related]
2. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.
Young RC; Walton LA; Ellenberg SS; Homesley HD; Wilbanks GD; Decker DG; Miller A; Park R; Major F
N Engl J Med; 1990 Apr; 322(15):1021-7. PubMed ID: 2181310
[TBL] [Abstract][Full Text] [Related]
4. Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy.
Colombo N; Chiari S; Maggioni A; Bocciolone L; Torri V; Mangioni C
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S47-51. PubMed ID: 7835811
[TBL] [Abstract][Full Text] [Related]
5. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
6. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
7. Therapy of advanced ovarian juvenile granulosa cell tumors.
Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
[TBL] [Abstract][Full Text] [Related]
8. Management of borderline tumors of the ovary: state of the art.
Tropé C; Kaern J
Semin Oncol; 1998 Jun; 25(3):372-80. PubMed ID: 9633850
[TBL] [Abstract][Full Text] [Related]
9. [Strategy for the ovarian cancer treatment].
Ochiai K
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2454-60. PubMed ID: 8279841
[TBL] [Abstract][Full Text] [Related]
10. [Borderline tumors of the ovary: a multicenter study in 137 patients].
Bonnamy L; Fignon A; Fetissof F; Berger C; Body G; Lansac J
J Gynecol Obstet Biol Reprod (Paris); 2001 May; 30(3):272-81. PubMed ID: 11398004
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
12. Gynecologic malignancies.
Schilder RJ; Scher RM; Young RC
Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
[TBL] [Abstract][Full Text] [Related]
13. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.
Harrison ML; Hoskins P; du Bois A; Quinn M; Rustin GJ; Ledermann JA; Baron-Hay S; Friedlander ML
Gynecol Oncol; 2006 Feb; 100(2):233-8. PubMed ID: 16321429
[TBL] [Abstract][Full Text] [Related]
14. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
15. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland.
Kumpulainen S; Kuoppala T; Leminen A; Komulainen M; Puistola U; Sankila R; Mäkinen J; Grénman S
Acta Obstet Gynecol Scand; 2007; 86(5):610-4. PubMed ID: 17464592
[TBL] [Abstract][Full Text] [Related]
16. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of malignant germ cell tumors of the ovary: a clinical analysis of 233 cases].
Zhang R; Hong W; Liu L
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):155-7. PubMed ID: 10920972
[TBL] [Abstract][Full Text] [Related]
19. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
20. Conservative surgery for borderline ovarian tumors: a review.
Tinelli R; Tinelli A; Tinelli FG; Cicinelli E; Malvasi A
Gynecol Oncol; 2006 Jan; 100(1):185-91. PubMed ID: 16216320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
